Publication | Closed Access

Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer

Breast OncologyMedicineCmf Versus CefPrimary Breast CancerRandomised ComparisonBreast CancerCancer TreatmentOncologyRadiation OncologyRadiologyHealth Sciences